Q32 Bio Inc QTTB.OQ QTTB.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Q32 Bio Inc is for a loss of 98 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Q32 Bio Inc is $8.00, about 75% above its last closing price of $2.00
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.20 | -1.23 | -0.90 | Beat | 26.8 |
Dec. 31 2025 | -1.50 | -1.51 | -1.16 | Beat | 23.2 |
Sep. 30 2024 | -1.40 | -1.40 | -1.46 | Missed | -4 |
Jun. 30 2024 | -1.05 | -1.04 | -1.42 | Missed | -36.2 |
Mar. 31 2024 | -1.42 | -2.32 | -14.95 | Missed | -543.5 |
Dec. 31 2023 | -5.40 | -5.40 | -5.04 | Beat | 6.7 |
Sep. 30 2023 | -7.56 | -7.56 | -10.26 | Missed | -35.7 |
Jun. 30 2023 | -8.94 | -8.55 | -10.98 | Missed | -28.4 |
This summary was machine generated August 4 at 12:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)